MaxCyte, Inc. (MXCT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

MaxCyte, Inc. (MXCT) Healthcare & Pipeline Overview

MaxCyte, Inc. pioneers next-generation cell therapies through its proprietary electroporation technology. The company's ExPERT platform enables efficient cell engineering for drug discovery, protein production, and therapeutic development, positioning it as a key player in the rapidly evolving cell therapy landscape within the medical devices sector.

What Is the Investment Thesis for MXCT?

MaxCyte's investment thesis centers on its proprietary electroporation technology and its potential to drive growth in the rapidly expanding cell therapy market. With a market capitalization of $148M and a gross margin of 68.4%, the company demonstrates strong potential for profitability despite its current negative profit margin of -135.1%. Key value drivers include the increasing adoption of MaxCyte's ExPERT platform by pharmaceutical and biotechnology companies for cell therapy development and manufacturing. Growth catalysts include the expansion of MaxCyte's product portfolio, strategic partnerships, and regulatory approvals for cell therapies utilizing its technology. However, potential risks include competition from alternative cell engineering technologies and the inherent challenges associated with the development and commercialization of novel cell therapies. The company's beta of 1.45 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

MXCT Key Highlights

Market Cap of $148M reflects the company's current valuation in the market.

• Gross Margin of 68.4% indicates strong pricing power and efficient cost management in its operations.
• Profit Margin of -135.1% highlights current challenges in achieving profitability, requiring close monitoring of expense management and revenue growth.
• Beta of 1.45 suggests higher volatility compared to the market, indicating potential for significant price fluctuations.
• No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than distributing profits to shareholders.

Who Are MXCT's Competitors?

MXCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MXCT's Key Strengths?

Proprietary electroporation technology.

• Established customer base.
• Comprehensive product portfolio.
• Strong intellectual property.

What Are MXCT's Weaknesses?

Negative profit margin.

• Reliance on a single technology platform.
• Limited geographic presence.
• Small employee base.

What Could Drive MXCT Stock Higher?

Regulatory approvals for cell therapies utilizing MaxCyte's technology.

• Expansion of strategic partnerships with pharmaceutical companies.
• Increasing adoption of MaxCyte's ExPERT platform by research institutions.
• Launch of next-generation electroporation platforms.

What Are the Key Risks for MXCT?

Financial-distress signal — its Altman Z-Score of 1.62 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-22.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from alternative cell engineering technologies.
• Regulatory hurdles for cell therapy products.
• Economic downturn affecting research funding.
• Technological obsolescence.
• Dependence on key personnel.

What Are the Growth Opportunities for MXCT?

• Expansion into New Therapeutic Areas: MaxCyte has the opportunity to expand its presence in emerging therapeutic areas, such as gene editing and immunotherapy. By leveraging its electroporation technology, MaxCyte can facilitate the delivery of gene editing tools and immunotherapeutic agents into cells, enabling the development of novel therapies for a wider range of diseases. The gene editing market is projected to reach $7.5 billion by 2028, while the immunotherapy market is expected to reach $25 billion by 2027, presenting significant growth opportunities for MaxCyte.
• Strategic Partnerships with Pharmaceutical Companies: MaxCyte can pursue strategic partnerships with pharmaceutical companies to co-develop and commercialize cell therapies utilizing its electroporation technology. These partnerships can provide MaxCyte with access to funding, expertise, and distribution channels, accelerating the development and commercialization of its products. The pharmaceutical industry is increasingly investing in cell therapies, creating opportunities for MaxCyte to collaborate with leading pharmaceutical companies and expand its market reach.
• Development of Next-Generation Electroporation Platforms: MaxCyte can invest in the development of next-generation electroporation platforms with enhanced capabilities, such as improved cell viability, higher transfection efficiency, and greater scalability. These advancements can further differentiate MaxCyte's technology from competing platforms and attract new customers. The market for cell engineering technologies is constantly evolving, requiring continuous innovation to maintain a competitive edge.
• Geographic Expansion into Emerging Markets: MaxCyte can expand its geographic presence into emerging markets, such as Asia-Pacific and Latin America, where the demand for cell therapies is growing rapidly. These markets offer significant growth opportunities for MaxCyte, as they are characterized by large patient populations and increasing healthcare spending. However, entering these markets requires careful consideration of regulatory requirements, cultural differences, and competitive landscapes.
• Expansion of Disposable Processing Assemblies (PAs) Portfolio: MaxCyte can expand its portfolio of disposable processing assemblies (PAs) to support a wider range of cell types and applications. These PAs are essential for the efficient and sterile processing of cells during electroporation, and expanding the portfolio can enhance MaxCyte's value proposition to its customers. The market for disposable bioprocessing products is growing rapidly, driven by the increasing demand for cell and gene therapies.

What Are MXCT's Competitive Advantages?

• Proprietary electroporation technology with proven efficacy.
• Established customer base in the pharmaceutical and biotechnology industries.
• Comprehensive product portfolio including instruments, disposables, and software.
• Strong intellectual property protection for its core technology.

What Does MXCT Do?

MaxCyte, Inc., founded in 1998 and headquartered in Rockville, Maryland, is a global life sciences company dedicated to the discovery, development, and commercialization of next-generation cell therapies. The company's core technology revolves around its proprietary electroporation platform, which facilitates the efficient and scalable introduction of molecules into cells for various applications. MaxCyte's product portfolio includes the ExPERT family of instruments: the ExPERT ATx for small to medium scale transfection, the ExPERT STx for protein production and drug development, the ExPERT GTx for large-scale therapeutic applications, and the ExPERT VLx for very large volume cell-engineering. These instruments are complemented by disposable processing assemblies (PAs), electroporation buffer solutions, and software protocols, providing a comprehensive solution for cell engineering. MaxCyte's technology is utilized by a diverse range of customers, including pharmaceutical companies, biotechnology firms, and academic research institutions, for applications spanning drug discovery, protein production, cell-based assays, and the development of novel cell therapies. The company's focus on innovation and its commitment to advancing cell therapy technologies have established it as a prominent player in the medical devices sector.

What Products and Services Does MXCT Offer?

• Develops and commercializes cell therapy technologies.
• Offers the ExPERT platform for cell engineering.
• Provides electroporation instruments for various scales of transfection.
• Supplies disposable processing assemblies (PAs) for cell processing.
• Offers electroporation buffer solutions and software protocols.
• Enables drug discovery and protein production through cell engineering.
• Facilitates the development of novel cell therapies.

How Does MXCT Make Money?

• Sells ExPERT electroporation instruments to pharmaceutical, biotech, and academic customers.
• Generates revenue from the sale of disposable processing assemblies (PAs).
• Provides electroporation buffer solutions and software protocols.
• Forms strategic partnerships with pharmaceutical companies for co-development and commercialization.

What Industry Does MXCT Operate In?

MaxCyte operates within the rapidly evolving cell therapy market, which is experiencing significant growth driven by advancements in cell engineering technologies and the increasing prevalence of chronic diseases. The market is characterized by intense competition, with numerous companies developing innovative cell therapies and cell engineering platforms. MaxCyte's proprietary electroporation technology positions it as a key player in this landscape, offering a unique solution for efficient and scalable cell engineering. The company competes with other cell engineering technology providers and cell therapy developers, requiring continuous innovation and strategic partnerships to maintain its competitive edge.

Who Are MXCT's Key Customers?

• Pharmaceutical companies developing cell therapies.
• Biotechnology firms engaged in drug discovery and protein production.
• Academic research institutions conducting cell engineering research.
• Contract manufacturing organizations (CMOs) providing cell therapy manufacturing services.

Wall Street analysts project MaxCyte, Inc. revenue of about $31.1M for fiscal 2026, with EPS near $-0.27. The estimate reflects 4 contributing analysts.

MaxCyte, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 12.4% above estimates on average.

MaxCyte, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.62 places it in the distress zone, a signal of elevated financial risk.

Return on equity for MaxCyte, Inc. stands at -22.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.8%, the inverse of the P/E and a quick read on earnings relative to price.

MaxCyte, Inc. (MXCT) Valuation Context

Valued at $148M, MXCT is classified as a micro-cap stock. Relative to its peer group, MXCT's quantitative score of 27/100 is below the peer average of 64/100.

MXCT Revenue & Earnings Trend

In Q2 2026, MXCT generated $7.3M in top-line revenue, marking a sequential decrease of 24.7%. The company recorded a net loss of $8.9M, with diluted EPS of $-0.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, MXCT averaged $-0.08 in diluted EPS.

Company Profile

MaxCyte, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Maher Masoud. MXCT has traded publicly since 2021.

MXCT Financials

MXCT Latest News

MXCT Analyst Consensus

MXCT MoonshotScore

Common Questions About MXCT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources